Insight report on Bipolar Disorder – Japan Drug Forecast and Market Analysis 2024 according to new research report

MarketResearchReports.Biz announces addition of new report” Bipolar Disorder – Japan Drug Forecast and Market Analysis to 2024 “to its database.

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsukas Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

GlobalData estimates that drug sales for bipolar disorder in Japan reached $373.4m during 2014, making it the second largest market within the 8MM. The market is expected to grow starting from 2020, driven by the saturation of generic erosion and the uptake of novel pipeline agents.

View Report At :


– Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for the top drugs in Japan from 2014-2024.

– Analysis of the impact of key events as well the drivers and restraints affecting Japan Bipolar Disorder market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Bipolar Disorder.

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of drug performance

– Obtain sales forecast for drugs from 2014-2024 in Japan.

Download Sample copy of this Report at

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.3 Symptoms

3.4 Prognosis

4 Disease Management

4.1 Diagnosis Overview

4.1.1 Clinical Evaluation

4.1.2 Screening Tools

4.2 Treatment Overview

4.2.1 Treatment Initiation and Maintenance Therapy

4.2.2 Manic or Mixed Episodes

4.2.3 Acute Agitation

4.2.4 Hypomanic Episodes

4.2.5 Major Depressive Episodes

4.2.6 Rapid Cycling

4.2.7 Cyclothymia

4.2.8 Other Treatment Factors

4.3 Treatment Guidelines and Leading Prescribed Drugs

4.4 Japan

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles – Major Brands

5.2.1 Lithium

5.2.2 Anticonvulsants

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074